193 related articles for article (PubMed ID: 8746920)
1. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
Johnson RE; Eissenberg T; Stitzer ML; Strain EC; Liebson IA; Bigelow GE
Drug Alcohol Depend; 1995 Nov; 40(1):17-25. PubMed ID: 8746920
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.
Johnson RE; Eissenberg T; Stitzer ML; Strain EC; Liebson IA; Bigelow GE
Drug Alcohol Depend; 1995 Nov; 40(1):27-35. PubMed ID: 8746921
[TBL] [Abstract][Full Text] [Related]
3. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
Strain EC; Stitzer ML; Liebson IA; Bigelow GE
J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
[TBL] [Abstract][Full Text] [Related]
6. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
[TBL] [Abstract][Full Text] [Related]
7. Effects of high-dose intravenous buprenorphine in experienced opioid abusers.
Umbricht A; Huestis MA; Cone EJ; Preston KL
J Clin Psychopharmacol; 2004 Oct; 24(5):479-87. PubMed ID: 15349002
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
13. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans.
Greenwald MK; Schuh KJ; Hopper JA; Schuster CR; Johanson CE
Psychopharmacology (Berl); 2002 Apr; 160(4):344-52. PubMed ID: 11919661
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.
Montoya ID; Gorelick DA; Preston KL; Schroeder JR; Umbricht A; Cheskin LJ; Lange WR; Contoreggi C; Johnson RE; Fudala PJ
Clin Pharmacol Ther; 2004 Jan; 75(1):34-48. PubMed ID: 14749690
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.
Ling W; Wesson DR; Charuvastra C; Klett CJ
Arch Gen Psychiatry; 1996 May; 53(5):401-7. PubMed ID: 8624183
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.
Comer SD; Collins ED; Fischman MW
Psychopharmacology (Berl); 2001 Feb; 154(1):28-37. PubMed ID: 11292003
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.
Schottenfeld RS; Chawarski MC; Mazlan M
Lancet; 2008 Jun; 371(9631):2192-200. PubMed ID: 18586174
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.
O'Connor PG; Oliveto AH; Shi JM; Triffleman EG; Carroll KM; Kosten TR; Rounsaville BJ; Pakes JA; Schottenfeld RS
Am J Med; 1998 Aug; 105(2):100-5. PubMed ID: 9727815
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
